nature research

Corresponding author(s):	Mark N. Adams
Last updated by author(s):	Jan 6, 2021

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

_				
		٠.	ist	
_	_	11		11 5
_	··	• •	J	

For	all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed
	$oxed{x}$ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	🗷 A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
X	A description of all covariates tested
	🗷 A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
x	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
X	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
	$oxed{x}$ Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.
So.	ftware and code

Policy information about <u>availability of computer code</u>

Data collection

No software was used.

Software: AmberTools 16 package (computational modelling); R statistical environment (bioinformatics analysis); GraphPad Prism V8 (statistical analysis)

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

All protein structures used in our computational methods are available from the Protein Data Bank (PBD codes 4BH6 and 4UI9). Previously generated RNAseq datasets are available from The Cancer Genome Atlas. Raw data for graphs and uncropped western blot images are available as supplemental data. (Uncropped images are being prepared during manuscript review).

Field-specific reporting				
· · · · · · · · · · · · · · · · · · ·	ne below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.			
x Life sciences	Behavioural & social sciences			
Life scier	nces study design			
All studies must dis	close on these points even when the disclosure is negative.			
Sample size	No sample size calculation was performed. For in vitro experiments, a minimum of three independent experiments were performed.			
Data exclusions	No data were excluded from the analyses.			
Replication	eriments were performed a minimum of three times. For viability assays, these were performed on three independent occasions in licate. All replicates are included within the manuscript.			
Randomization	Samples were blindly randomised for inclusion within experiments. For example, following of seeding cells into dishes for in vitro experiments, dishes were selected at random for either drug treatment (verus vehicle) or for transfection.			
Blinding	Authors were not blinded during in vitro data collection.			
We require informat system or method lis Materials & ex n/a Involved in the state of the system or method lis Materials & ex n/a Involved in the system or method lis X Antibodies X Palaeonto X Animals and S Human reserved X Clinical da X Dual use reserved	cell lines cell lines my ChIP-seq Flow cytometry ogy and archaeology d other organisms earch participants ca			
Antibodies Antibodies used	The CDCA3 antibody (HPA026587), monoclonal FLAG M2 antibody (F1804) and α -Tubulin antibody (T9026) were purchased from Sigma Aldrich. Antibodies against the HA tag (#3724) and phospho-CK2 substrate motif (#8738) were purchased from Cell Signaling Technology (Genesearch, Australia). The Cdh1 (ab77885) and γ H2AX (ab26350) antibodies were from Abcam. The FANCI antibody (A301-254A) was from Bethyl Laboratories. Donkey anti-rabbit and anti-mouse Alexa Fluor 488 antibodies were purchased from Life Technologies.			
Validation	Antibody specificity was validated in-house using siRNA or pharmacological techniques.			
Eukaryotic c	ell lines			
Policy information	about <u>cell lines</u>			
Cell line source(s)	All cell lines are commercially available. All cells with the were from the American Type Culture Collection (ATCC) with the exception of EBC-1 which were purchased from Cell Bank Australia.			
Authentication Frozen stocks of all cell lines were made within 5 passages of purchase from vendors. All experiments we cells grown from original stocks. To verify technique, several cell lines were STR profiled at the Genomics (Brisbane, Australia).				

All cell lines tested negative for mycoplasma.

Name any commonly misidentified cell lines used in the study and provide a rationale for their use.

Mycoplasma contamination

Commonly misidentified lines (See <u>ICLAC</u> register)